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Abstract:   
Regulation of cell volume is critical for many cellular and organismal functions, yet the 
molecular identity of a key player, the volume-regulated anion channel VRAC, has remained 
unknown. A genome-wide siRNA screen in mammalian cells identified LRRC8A as a VRAC 
component. LRRC8A formed heteromers with other LRRC8 multispan membrane proteins. 
Genomic disruption of LRRC8A ablated VRAC currents. Cells with disruption of all five 
LRRC8 genes required LRRC8A co-transfection with other LRRC8 isoforms to reconstitute 
VRAC currents. The isoform combination determined VRAC inactivation kinetics. Taurine flux 
and regulatory volume decrease also depended on LRRC8 proteins. Our work shows that 
VRAC defines a class of anion channels, suggests that VRAC is identical to the volume-
sensitive organic osmolyte/anion channel VSOAC, and explains the heterogeneity of native 
VRAC currents.  
 
 
One Sentence Summary: 
We show that the swelling-activated anion channel VRAC represents a structurally new class 
of anion channels that also conducts organic osmolytes. 
 
 
 
Main Text: 
Cells regulate their volume to counteract swelling or shrinkage caused by osmotic challenges 
and during processes like cell growth, division, and migration. As water transport across 
cellular membranes is driven by osmotic gradients, cell volume regulation requires 
appropriate changes of intracellular concentrations of ions or organic osmolytes like taurine 
(1, 2). Regulatory volume decrease (RVD) follows the extrusion of intracellular Cl- and K+ and 
other osmolytes across the plasma membrane. A key player is the volume-regulated anion 
channel VRAC that mediates characteristic swelling-activated Cl--currents (ICl(swell)) and is 
ubiquitously expressed in vertebrate cells (3-5). Nearly inactive under resting conditions, 
VRAC slowly opens upon hypotonic swelling. The mechanism behind VRAC opening 
remains enigmatic. VRAC currents are outwardly rectifying (hence the alternative name 
VSOR for volume-stimulated outward rectifier (4, 5)) and show variable inactivation at inside-
positive voltages. VRAC conducts iodide better than chloride and might also conduct organic 
osmolytes like taurine (6) (hence VSOAC, volume-stimulated organic osmolyte/anion 
channel (7)), but this notion is controversial (8-10). VRAC is believed to be important for cell 
volume regulation and swelling-induced exocytosis (11), and also for cell cycle regulation, 
proliferation and migration (1, 3, 4). It may play a role in apoptosis and various pathological 
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states including ischemic brain edema and cancer (4, 12). Progress in the characterization of 
VRAC and its biological roles has been limited by the failure to identify the underlying 
protein(s) despite efforts for decades (1, 5). ClC-2 Cl--channels activate upon cell swelling, 
but their inward rectification and Cl- over I- selectivity deviate from VRAC (13) Drosophila 
dBest1, a member of a family of Ca2+-activated Cl--channels, mediates swelling-activated Cl--
currents in insect cells (14, 15), but their characteristics differ from VRAC currents and the 
mammalian homolog of dBest1 is swelling-insensitive (16). We show that VRAC represents a 
distinct class of anion channels that also conduct organic osmolytes. 
To identify VRAC, we opted for a genome-wide RNA interference screen that could 
identify non-redundant VRAC components. Swelling-induced iodide influx into HEK cells 
expressing the iodide-sensitive yellow fluorescent protein YFP(H148Q/I152L) (17) was used 
as read-out in a fluorometric imaging plate reader (Fig. 1A). Exposure to saline containing 
50 mM iodide entailed a slow fluorescence decay under isotonic conditions, whereas 
hypotonicity induced a delayed increase in YFP quenching (Fig. 1B) that could be reduced 
by VRAC inhibitors like carbenoxolone (18) (fig. S1). In a prescreen targeting 21 anion 
transporters (table S1), only siRNAs against the Cl-/HCO3- exchanger AE2 gave significant 
effects (Fig. 1B). They decreased iodide influx under both isotonic and hypotonic conditions.  
Our genome-wide screen utilized three separately transfected siRNAs per gene (fig. S2). 
Offline data analysis (fig. S3, A and B) yielded the maximal slope of fluorescence quenching 
that was used to define hits. Further criteria included the presence of predicted 
transmembrane domains and a wide expression pattern. 87 genes (table S2) were taken into 
a secondary screen with independent siRNAs. Of these, only suppression of LRRC8A 
robustly slowed hypotonicity-induced YFP quenching (Fig. 1C). LRRC8A knock-down also 
strongly suppressed ICl(swell) in patch-clamp experiments (Fig. 1, D to F), suggesting that the 
multispan membrane protein LRRC8A is an indispensable component of VRAC or is needed 
for its activation. 
Although LRRC8A reached the plasma membrane (fig. S4A for HeLa cells), its 
transfection into HEK cells rather decreased ICl(swell) (Fig. 1F). We hypothesized that VRAC 
contains LRRC8A as part of a heteromer and that LRRC8A overexpression led to a subunit 
stoichiometry that was incompatible with channel activity. LRRC8A has four closely related 
homologs (LRRC8B - LRRC8E) which all have four predicted transmembrane domains (19, 
20). EST databases suggested that all homologs were widely expressed. 
Immunocytochemistry of transfected HeLa cells (fig. S4A) and of native HEK cells (Fig. 1, G 
and H) detected LRRC8A at the plasma membrane. Truncation of its carboxy-terminus as in 
a patient with agammaglobulinemia (21) led to cytoplasmic retention (fig. S4B). LRRC8B 
through LRRC8E remained intracellular when transfected alone, but reached the plasma 
membrane when co-transfected with LRRC8A (Fig. 1, I and J, fig. S4, C to H). Unlike 
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LRRC8A transfection, LRRC8A/LRRC8C co-expression did not suppress ICl(swell) (Fig. 1F). 
However, neither this co-expression, nor any other combination tested, significantly 
increased current amplitudes above WT levels.  
We used zinc-finger nuclease and CRISPR/Cas (22) technologies to constitutively disrupt 
LRRC8 genes. Besides polyploid HEK cells we used stably diploid human HCT116 cells for 
increased disruption efficiency. Gene disruption was confirmed by sequencing and Western 
blots (Fig. 2A, table S3). To exclude off-target effects, we generated two HEK and three 
HCT116 lines in which LRRC8A was disrupted at different positions (tables S3 and S4). 
ICl(swell) was abolished in all five lines and could be rescued by LRRC8A transfection (Fig. 2, B 
and C, and fig. S5), proving that LRRC8A is essential for ICl(swell). We also produced HCT116 
cells in which other LRRC8 genes were disrupted singly or in combinations, including a line 
with disruption of all five LRRC8 genes (henceforth called LRRC8-/- cells). Except for 
LRRC8A, disruption of single LRRC8 genes did not abolish VRAC currents (Fig. 2, B and C). 
However, ICl(swell) amplitudes were robustly reduced in LRRC8E-/- and in LRRC8(C/E)-/- double 
and LRRC8(C/D/E)-/- triple knock-out (KO) cells. ICl(swell) was abolished in LRRC8(B/C/D/E)-/- 
cells (Fig. 2, B and C). ICl(swell) inactivated faster and at less positive potentials in 
LRRC8C-/- and LRRC8(C/E)-/- cells compared to wild-type (WT) HCT116, LRRC8B-/-, 
LRRC8D-/- or LRRC8E-/- cells. By contrast, ICl(swell) inactivated more slowly and at more 
positive voltages in LRRC8(D/E)-/- HTC116 cells (Fig. 2, B and D, and fig. S6D) and in WT 
HEK cells (Fig. 1E). ICl(swell) of these mutant cell lines retained the characteristic I->NO3->Cl-
>>gluconate permeability sequence (fig S6A). 
LRRC8A transfection into quintuple KO LRRC8-/- cells failed to rescue ICl(swell) (Fig. 2, E 
and F), agreeing with the absence of ICl(swell) in LRRC8(B/C/D/E)-/- cells (Fig. 2, B and C). Co-
transfecting LRRC8-/- cells with LRRC8A and either LRRC8C or LRRC8E yielded ICl(swell) with 
current densities similar to native cells (Fig. 2F). Co-expressing LRRC8A with LRRC8D 
yielded lower currents (Fig. 2, E and F). No current was observed upon LRRC8A+B co-
expression, which may relate to the poor expressibility of LRRC8B (Fig. 3, D and F). These 
findings fit to the low currents of LRRC8(C/E)-/- cells (Fig. 2C) where LRRC8A can only 
interact with poorly expressible LRRC8B and/or LRRC8D. Reconstituted ICl(swell) activated like 
WT VRAC upon swelling (Fig. 2E) and displayed its typical anion permeability sequence (fig. 
S6, B and C). 
ICl(swell) inactivated more slowly and at more positive voltages when LRRC8A was co-
expressed with LRRC8C in LRRC8-/- cells compared to cells co-expressing LRRC8A with 
LRRC8E or LRRC8D (Fig. 2, E and G, and fig. S6E). This observation agreed with the faster 
ICl(swell) inactivation in LRRC8C-/- cells (Fig. 2, B and D, and fig. S6D) in which the 
‘decelerating’ LRRC8C subunit may be replaced by LRRC8E or other ‘accelerating’ subunits.  
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Native ICl(swell) currents display different inactivation kinetics (3). Whereas ICl(swell) shows 
prominent inactivation at positive potentials in HEK (23, 24) (Fig. 1E, Fig. 2D, and fig. S6D) 
and even more so in HCT116 cells (Fig. 2, B and D, and fig. S6D), it inactivates much less in 
blood cells like promyelocytic HL-60 cells, and in vascular smooth muscle and neurons (24-
26). EST databases suggest that these cells express the ‘decelerating’ subunit LRRC8C, but 
lack LRRC8E that potently induces inactivation (Fig. 2, E and G, and fig. S6E). Quantitative 
RT-PCR confirmed that HEK and HCT116 cells expressed LRRC8A through LRRC8E, 
whereas LRRC8E was almost absent from HL-60 cells (fig. S7). Moreover, HCT116 cells, 
whose ICl(swell) inactivates more than that of HEK cells (Fig. 1E, Fig. 2, B and D, and fig. S6D), 
express less ‘decelerating’ LRRC8C than HEK (fig. S7).   
LRRC8 proteins have four predicted transmembrane domains (TMDs) followed by 
hydrophilic C-termini with up to 17 leucine-rich repeats (27) (hence LRRC8 = leucine-rich 
repeat containing 8) (Fig. 3A). Their C-termini were originally thought to be extracellular (19, 
21), but proteome databases revealed (20) that the TMD2-TMD3 linker can be 
phosphorylated and suggested that LRRC8 N- and C-termini are cytoplasmic (Fig. 3A). 
LRRC8 proteins display weak homology (20) to pannexins, pore-forming proteins (28) with 
connexin-like topology. Connexins form hexameric hemichannels and gap junctions (29). 
This similarity suggested (20) that LRRC8 proteins form hexameric channels for so far 
unknown substrates. Just like VRAC currents (14, 15, 30), LRRC8 proteins are found in 
vertebrates, but not in other phyla like arthropoda (20). 
We ascertained the pannexin- and connexin-like transmembrane topology of LRRC8A. 
Mutating potential N-linked glycosylation sites between TMD1 and TMD2 abolished the size 
shift upon PNGaseF treatment (Fig. 3B), demonstrating that this loop is extracellular. 
Immunofluorescence of cells transfected with HA-tagged LRRC8A constructs showed that 
the TMD3-4 segment is extracellular and the C-terminus cytoplasmic (Fig. 3C).  
The formation of LRRC8 heteromers was confirmed by co-immunoprecipitation from HEK 
cells transfected with LRRC8A and epitope-tagged versions of either LRRC8B, C, D, or E. 
LRRC8A co-precipitated each of the other isoforms, but not the Cl--channel ClC-1 used as 
control (Fig. 3, D and E). Conversely, precipitation of epitope-tagged versions of LRRC8B 
through LRRC8E brought down LRRC8A (Fig. 3F). Co-precipitation of LRRC8 isoforms was 
also observed for native HEK cells (fig. S8). 
Hypotonicity induced a robust taurine efflux from HEK and HCT116 cell lines, but not from 
their LRRC8A-/- derivates (Fig. 4A and fig. S9A) where it could be rescued by 
LRRC8A/LRRC8C co-transfection (fig. S9B for HEK). Taurine efflux was also abolished in 
LRRC8(B/C/D/E)-/- HCT116 cells (Fig. 4A). Since both ICl(swell) and swelling-induced taurine 
efflux similarly depended on LRRC8 heteromers, VRAC is most likely identical to VSOAC, 
the volume-stimulated organic osmolyte/anion channel (7). Accordingly, LRRC8A-/- HEK cells 
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showed severely impaired volume regulation. After initial swelling, WT, but not LRCC8A-/- 
cells slowly reduced their cell volume in the continuous presence of extracellular hypotonicity 
(Fig. 4B). Hence, LRRC8-containing VSOAC is a major player in RVD. 
The identification of LRRC8 proteins as crucial VRAC constituents ends a decades-long 
hunt for the elusive molecular identity of this important channel. The absence of ICl(swell) upon 
genomic disruption of LRRC8A and its rescue by transient re-expression identified LRRC8A 
as an indispensable component of VRAC, or alternatively as being crucial for its activation. 
The wide expression pattern of LRRC8 genes and the plasma membrane residency of 
LRRC8A-containing heteromers are fulfilled prerequisites for LRRC8 proteins forming the 
channel. The dependence of current properties on LRRC8 isoform combinations indicated 
that LRRC8 heteromers are integral components of VRAC, a notion buttressed by the 
homology of LRRC8 proteins to pannexins. Since co-transfection of LRRC8 isoforms failed to 
significantly increase ICl(swell) amplitude over WT levels other factors limit VRAC activity. Such 
a limiting component might be an auxiliary subunit of VRAC or could be part of the signaling 
cascade leading to its activation. Indeed VRAC currents seem to be highly regulated, with 
amplitudes differing only 2-3fold across cell types (3, 30).  
The homology between LRRC8 proteins and pannexins suggested that LRRC8 proteins 
form hexameric channels (20). We confirmed the pannexin-like topology of LRRC8A and 
propose that VRAC is formed by LRRC8 hexamers of LRRC8A and minimally one other 
family member. In this model, VRAC may contain two to five different LRRC8 isoforms. This 
could create a large variety of VRAC channels with different properties. The variation of 
ICl(swell) inactivation kinetics between different tissues and cells (3) can now be ascribed to 
different expression ratios of LRRC8 isoforms. LRRC8-dependent Cl-- and taurine-fluxes 
indicated that VRAC is identical to VSOAC (6) and fit to a pore formed by LRRC8 hexamers 
because hexameric pannexin channels likewise display poor substrate specificity (28).  
Our work provides the basis to explore the structure-function relationship of 
VRAC/VSOAC, to clarify the signal transduction from cell volume increase to channel 
opening, and to investigate the role of the channel in basic cellular processes like cell 
division, growth, and migration and in various pathological states. Interestingly, a truncating 
LRRC8A mutation has been described in a patient with agammaglobulinemia (21) and 
LRRC8C may have a role in fat metabolism (31). 
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Fig. 1. siRNA screen for volume-regulated anion channel VRAC identifies LRRC8A.  
(A) Principle of screen. Top, in regulatory volume decrease (RVD) VRAC releases chloride. 
Below, quenching of YFP fluorescence by iodide entering through VRAC used as read-out. 
(B) Example traces, normalized to fluorescence at ~30-50 s. Averaged from wells treated 
with control siRNAs (scrambled, AE2, both n=3) and no siRNA (n=2) (error bars, SEM), and 
individual traces from wells singly transfected with the 3 siRNAs against LRRC8A. Except for 
LRRC8A siRNA2 and 3, all traces are from the same plate. Arrow indicates addition of 
iodide-containing hypotonic (hypo; 229 mOsm) or isotonic (iso; 329 mOsm) saline. (C) 
Secondary screen using siRNA pools against candidate genes. Averaged control traces as 
above. (D) Typical time course of VRAC activation in WT or LRRC8A siRNA-treated HEK 
cells. Current densities at -80 mV are shown. Bar, application of hypotonic (240 mOsm) 
saline (hypo).  (E) Current traces of fully activated ICl(swell) measured using the protocol shown 
below. Dotted lines indicate zero current. (F) ICl(swell) amplitudes (at -80 mV) of WT HEK cells, 
cells treated with LRRC8A siRNA, or transfected with indicated LRRC8 cDNAs. Error bars, 
SEM; number of experiments is indicated; ***, p<0.001. (G) Plasma membrane localization of 
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endogenous LRRC8A in HEK cells. (H) No LRRC8 labeling in LRRC8A-/- HEK cells. (I) 
LRRC8C is intracellular when transfected into HeLa cells, but (J) reaches the plasma 
membrane when co-transfected with LRRC8A. Inset, magnification of boxed area showing 
only GFP-fluorescence. Scale bars, 10 μm.   
 
Fig. 2. Characterization of LRRC8 KO cells and of reconstituted ICl(swell). (A) Western 
blots confirm LRRC8A disruption in mutant cell lines (table S3). α-tubulin, loading control. (B) 
Example ICl(swell) traces (as in Fig. 1E, but 2-s pulses) of WT and mutant HCT116 cells. (C) 
Current densities (at -80mV) of maximally activated ICl(swell) of WT and mutant HCT116 cells. 
(D) ICl(swell) inactivation assessed by ratio of current at end/beginning of pulse. (E) When 
transfected into HCT116 LRRC8-/- cells (with all LRRC8 genes disrupted), LRRC8A rescues 
ICl(swell) only with LRRC8C, D or E. Left, example ramp current traces from reconstituted 
ICl(swell) at isotonicity (black), 2 minutes after switching to hypotonicity (green) and with 
maximal activation (red). (F) ICl(swell) current densities at -80mV for indicated combinations. 
(G) Voltage-dependent inactivation of ICl(swell). Error bars, SEM. Number of cells in brackets. *, 
p<0.05 **, p<0.01 and ***, p<0.001 vs. WT. 
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Fig. 3. Transmembrane topology and heteromerization of LRRC8A. (A) LRRC8 model 
(modified from (20)). Four transmembrane domains precede a C-terminus with up to 17 
leucine-rich repeats (27) (orange). Phosphoserines in LRRC8A (red P) and LRRC8D (blue P) 
according to Uniprot (32), predicted N-linked glycosylation sites (Y) and added epitopes are 
indicated. (B) PNGaseF treatment of endogenous LRRC8A, transfected LRRC8A, but not of 
LRRC8A(N66A,N83A) with disrupted glycosylation sites, decreased LRRC8A size in 
Western blots. The changed banding pattern of LRRC8A(N66A,N83A) suggests altered 
posttranslational modifications. n.t., non-transfected. (C) Immunofluorescence of non-
permeabilized and permeabilized HeLa cells transfected with HA-tagged GFP-LRRC8A. 
Overlays of GFP (green) and HA (red) labeling. Insets show exclusively HA-staining. Scale 
bar, 20 μm. (D) LRRC8A co-precipitated epitope-tagged LRRC8B through LRRC8E in 
double-transfected HEK cells. LRRC8B and LRRC8D were poorly expressible. (E) LRRC8A 
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did not co-precipitate the ClC-1 Cl- channel. (F) Epitope-tagged LRRC8B through LRRC8E 
co-precipitated LRRC8A.  
 
Fig. 4. LRRC8 proteins are crucial for swelling-induced taurine efflux and RVD.  
(A) 3[H]-taurine efflux from HCT116 cells of indicated genotypes. Cells were either in isotonic 
solution throughout (WT, white bars), or exposed to hypotonic solution starting at t=0 
(arrows). Bars, means of 6 measurements; error bars, SEM. (B) WT and LRRC8A-/- HEK 
cells were shifted to hypotonic saline (96 mOsm) at t=30s and cell volume was monitored by 
calcein fluorescence. Mean of 6 measurements; error range, SEM. Similar results obtained in 
3 experiments.  
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Materials and Methods 
HEK293-YFP Cell Line Used in the siRNA Screen 
The T-REx® system (Life Technologies) was used to generate a stable HEK293 cell line 
inducibly expressing the halide-sensitive YFP(H148Q/I152L) (17). Clones were selected 
using 200 µg/ml hygromycin B and 10 µg/ml blasticidin. Monoclonal cell lines were 
subsequently tested for robust and homogenous expression of YFP after induction with 1.25 
μg/ml doxycycline using life-cell imaging. The clone 1:5-(6) was chosen for the genome-wide 
screening procedure. The cells were kept in DMEM with tetracycline-free Hyclone FCS 
(Thermo Scientific) and the above-mentioned antibiotics.  
Genome-wide siRNA Screen 
The screen was performed at the FMP Screening Unit using the Ambion Silencer® Human 
Genome siRNA Library V3 (Life Technologies) containing 189 384-well plates. This library 
targets each gene by three independently placed siRNAs. The screen was performed in two 
replicates. Each screening plate contained several controls like siRNA pools against YFP 
(Silencer GFP siRNA from Ambion), a non-targeting siRNA (Silencer Negative Control from 
Ambion), an siRNA pool against AE2 (ON-TARGETplus SMARTpool siRNA SLC4A2  from 
Thermo Scientific) and a cell death-inducing siRNA mixture (AllStars Hs Cell Death Control 
siRNA from Qiagen). For detailed plate layout see fig. S2. For siRNA transfection, in each 
well of the 384-well assay-plate 8 µl of a 500 nM library-siRNA-OptiMEM® solution was mixed 
with 0.2 µl Lipofectamine® RNAimax transfection reagent (Life Technologies) previously 
diluted in 11.8 µl Opti-MEM® (Life Technologies). Subsequently 6000 cells/well in antibiotic-
free DMEM were seeded onto the pre-dispensed transfection mixture using a BioTek 
EL406TM dispenser resulting in a final concentration of 50 nM siRNA in a total volume of 80 µl 
per well. After 24 h the cell culture medium was exchanged to phenol red-free DMEM 
containing 1.25 μg/ml doxycycline to induce YFP-expression.  
The YFP-quenching assay was performed 72 h post-transfection. After having 
exchanged the cell culture medium in all wells of the plate with 10 μl of isotonic solution (in 
mM: 145 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, 10 HEPES pH 7.4, 329 mOsm) in a 
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Tecan Freedom EVO 200 workstation, the plates were transferred into the FLIPRTM 
(Molecular Devices) High Throughput Cellular Screening Device and fluorescence 
measurements were initiated. All wells of the plate were simultaneously illuminated at λ= 
495-505 nm and YFP-fluorescence was measured at λ= 526-585 nm using the FLIPR Fluo3 
LED/filter set. After 5 measurements in intervals of 5 s, parallel pipetting within the FLIPRTM 
added 25 μl iodide-containing hypotonic (rows 1-23) (in mM: 70 NaI, 5 NaCl, 5 KCl; 1 MgCl2, 
2 CaCl2, 10 glucose, 10 HEPES pH 7.4, 189 mOsm) or isotonic (row 24) (in mM: 70 NaI, 5 
NaCl, 5 KCl; 1 MgCl2, 2 CaCl2, 10 glucose, 140 mannitol, 10 HEPES pH 7.4, 329 mOsm) 
solution into each well. The solution added to wells O23, P23, O24 and P24 was hypotonic 
and contained 1% Triton X100. The mixture of the pre-existing 10 μl isotonic solution and the 
newly added 25 μl hypotonic solution resulted in a final osmolarity of 229 mOsm, i.e. a ~30% 
decrease in osmolarity, and a final concentration of 50 mM iodide. Fluorescence 
measurements were continued for 55 s in 5-s intervals, followed by 8 measurements in 30-s 
intervals to minimize bleaching, and finally 10 measurements in 1-s intervals. The total 
amount of measurement (500 s) was sufficient for YFP-quenching to nearly reach steady 
state. At time points 0 s and 5 s (before pipetting) and at 25, 30, 35, 40, 45, and 490 s 
(during/after pipetting) photographs of the entire plate were taken to allow post-hoc control of 
the integrity of the cell layers of each well. All original fluorescence traces were stored for re-
analysis.  
Parameters Extracted from FLIPRTM Screen and Bioinformatics Analysis 
Several parameters were extracted from the primary data and used for subsequent data 
evaluation (fig. S3, A and B).  The averaged fluorescence before the pipetting step, Fabsante, 
was obtained by averaging values from measurements 1-3 and was used to set a warning 
‘low cell’ flag when its value was less than 0.8 times of mean Fabsante averaged over all 
experimental wells from the plate. After pipetting, the fluorescence acutely changed to new 
values that were more or less stable for about 30 s before swelling-induced quenching of 
YFP set in. We averaged fluorescence values from measurements 9 to 12 to obtain Fabsstart 
which was subsequently used for normalization. Fabsfin was defined as averaged fluorescence 
from the four last measurements and we set another warning flag if fluorescence had not 
reached quasi-steady-state at the end of the measurement. Fabsfin might be used for 
background subtraction. We preferred, however, to subtract FBG TX100, the averaged (over the 
last 300 s) fluorescence of the four control wells from the same plate that had been exposed 
to Triton X100 to maximally quench YFP fluorescence. The background-subtracted 
fluorescence value of each well was then normalized to the corresponding Fabsstart value to 
yield F* (fig. S3B).  
siRNA-mediated knock-down of VRAC should reduce iodide current magnitude, but 
not necessarily the final intracellular iodide concentration (reflected in Fabsfin). Although not 
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being a linear function of iodide influx, the speed of YFP quenching after exposure to 
hypotonicity is the best indicator for the magnitude of VRAC currents. We therefore 
determined the slope of fluorescence change by linear regression of 11 points in a sliding 
window between 35 and 350 s. The maximum of these slopes was defined as Smax. The 
intersection of the corresponding linear regression line with F*=1 defined tonset as a measure 
for the speed of response to the hypotonic challenge, a delay that might be changed e.g. by 
interfering with the signal transduction cascade leading to VRAC opening (fig. S3B). For 
each individual plate we then calculated the mean maximal slope Smax
mean of all experimental 
wells and the corresponding standard deviation.  Smax
 of each individual siRNA-treated well 
was expressed in terms of standard deviations to yield Z-scores, with e.g. Z=2 meaning that 
the slope is slower by two standard deviations compared to the average of the plate.  
siRNAs leading to cell death or targeting YFP confirmed that results of none of the 
384-well plates had to be discarded because of low transfection efficiency. Results were 
sorted by genes and listed individually for each of the three siRNAs (which generally were on 
different plates) the Z-score, tonset, F
abs
ante, F
abs
fin, the low-cell and the non-steady-state flags 
(1 or 0). It also listed the protein families associated with the gene products (as obtained from 
UniProtKB database (32)), the genes’ tissue expression pattern (as determined by publicly 
available microarray data (33)) and predicted number of transmembrane domains that was 
calculated by the software TMHMM 2.0c (34). Comparison of the first and replicate screen 
showed that the effects of individual siRNAs on the respective Z-scores of Smax correlated 
reasonably well and demonstrated the usefulness of our warning flags (fig. S3, C and D). To 
account for different efficiencies of siRNA knock-down with the three individual siRNAs 
against each gene, some of which may be ineffective or show off-target effects, we sorted 
our results according to the mean Z obtained with the two ‘best’ siRNAs (giving the largest 
values of Z).  
As expected, many of the hits could be ruled out by one or more criteria. For instance, 
siRNAs against several ribosomal proteins led to large Z-scores that were caused by poor 
cell growth or cell death as indicated by the ‘low cell’ flag. Large Z-scores that were not 
reproduced in the replicate screen could sometimes be eliminated by examining the 
photographs of the plates which showed dirt at the respective well that had caused high 
background fluorescence. As we were looking for the channel itself and not for proteins 
involved in the activation of VRAC, we limited our search to proteins having at least one 
predicted transmembrane domain. Many candidates could be eliminated by their well-
established function or their inclusion in well-known gene families like olfactory receptors or 
other G-protein coupled receptors. However, as annotations are not always reliable and as 
proteins may serve more than one function, several candidates whose annotated function 
appeared to be incompatible with VRAC function but which otherwise seemed promising 
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were earmarked for a secondary screen. As VRAC currents have been observed in every 
mammalian tissue that has been investigated, we excluded candidates that showed a narrow 
tissue distribution or very low expression levels as indicated by NCBI EST profile databases 
or the scientific literature, except when they belonged to a gene family whose overlapping 
expression pattern covered many tissues.  
On the basis of these criteria 87 candidate genes (table S2) were selected for a 
secondary screen that used again the FLIPRTM assay with pools of four siRNAs (ON-
TARGETplus SMARTpool siRNA, Thermo Scientific) that were different from the ones used 
in the primary screen. Of these genes, only LRRC8A passed the test. The SMART pool 
directed against LRRC8A slowed hypotonicity-induced quenching of YFP fluorescence better 
than the SMART-pool against AE2 (Fig. 1C). It is interesting to note that LRRC8A was at the 
222nd position of hits sorted exclusively by the mean Z-score averaged across both screens 
from the 2 out of 3 siRNAs per gene that gave the best score. Only one of the three siRNAs 
against LRRC8A gave a Z-score for maximal slope of ~2, the two others were below 1 (fig. 
S3E). 
Generation of Monoclonal Knock-out Cell Lines Using the CRISPR/Cas and Zinc-finger 
Nuclease Technologies 
For the disruption of LRRC8 genes by the CRISPR/Cas system in cell culture, we used the 
px330 single plasmid system as described (22). The targeting sgRNA sequences were 
chosen using both the UCSC Genome Browser tool at www.genome-engineering.org and the 
sequence collection from (35) (for sequences, table S4).Target sgRNAs were cloned into the 
px330 vector and transfected into the described YFP expressing HEK293 clone or WT 
HCT116 cells in a 6-well format using 3 µl of the Fugene HD transfection reagent and 900 ng 
targeting vector(s) (up to 4) plus 100 ng pEGFP-C1-vector. In HCT116 cells, the LRRC8A 
gene was additionally disrupted using custom-designed CompoZr® Knock-out Zinc-Finger 
Nucleases (Sigma). The zinc-finger nuclease (ZFN) pair encoded on two separate plasmids 
was transfected as the CRISPR/Cas constructs described above, using 500 ng of each ZFN-
plasmid and 100 ng of the pEGFP-C1 vector. 2-5 days post-transfection single GFP-positive 
cells were FACS-sorted into 96-well plates containing preconditioned DMEM (for HEK cells) 
or McCoy’s 5A (for HCT116 cells) medium. In some cases, transfected cells were enriched 
by G418 selection before FACS sorting.  
Monoclonal cell lines were raised and tested for sequence alterations using target-site-
specific PCR on genomic DNA followed by Sanger-sequencing and/or Western blot analysis 
to confirm the absence of the protein when specific antibodies were available. To generate 
multiple KOs of several genes, the respective plasmids were transfected together, or cell 
lines already carrying LRRC8 gene disruptions were targeted again for other LRRC8 genes. 
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Antibodies 
Polyclonal antibodies against LRRC8A were raised in rabbits against the peptide 
QRTKSRIEQGIVDRSE that was coupled to KLH through an N-terminally added cysteine. Its 
sequence corresponds to LRRC8A protein sequence between TMD2 and TMD3. Polyclonal 
antibodies against the C-terminus of LRRC8E were raised in rabbits against the peptide 
LYEGLPAEVREKMEEE that was also coupled with an N-terminally added cysteine to KLH. 
Sera were affinity-purified against the respective peptide and proved specific in Western 
blots (Fig. 2A and fig. S10, A and B) and—for LRRC8A—in immunofluorescence (Fig. 1, G 
and H, and fig. S10C). The rabbit anti-KCC1 antibody was described previously (36). 
The following commercial primary antibodies were used: rabbit anti-myc (A-14, Santa Cruz 
Biotechnology), rabbit anti-GFP (A-11122, Life Technologies) for IP and chicken anti-GFP 
(1020, Aves Lab) for Western blot, mouse anti-α-tubulin (DM1A, Sigma), mouse anti-HA 
(HA.11, Covance). Secondary antibodies were conjugated to AlexaFluor 488 or 546 
(Molecular Probes) or to horseradish peroxidase (Jackson ImmunoResearch).  
Expression Constructs and Immunocytochemistry 
For expression of LRRC8A - E with GFP fused to their N-termini or C-termini, cDNA 
encoding the respective human protein (or only aa 1-719 for LRRC8Atrunc) was cloned with 
stop codon into pEGFP-C1 or without stop codon into pEGFP-N1, respectively. For 
expression of C-terminally RFP-tagged LRRC8A, the cDNA was cloned into pmRFP-N1. 
cDNA encoding human ClC-1 was in pEGFP-C1. For untagged (co-expression in 
electrophysiological experiments and LRRC8A antibody testing by Western blot) and C-
terminally myc-tagged (deglycosylation experiment and co-immunoprecipitations upon 
heterologous expression) expression, cDNA encoding LRRC8A was cloned (with and without 
stop codon, respectively) into pcDNA3.1/myc-His(-)B (Invitrogen). HA-tags (at T307 or at the 
extreme C-terminus of LRRC8A) and point mutations were introduced by PCR. All constructs 
were confirmed by sequencing the complete ORF. 
For immunocytochemistry, cells were transfected (if indicated) with plasmid encoding 
the respective construct(s) using Fugene HD. 24-36 h after transfection, cells were fixed in 
pre-cooled methanol at -20°C for 10 min (immunostaining with LRRC8A antibody), or in 2% 
(topology assay) or 4% PFA in PBS for 15 min followed by a 5-min incubation with 30 mM 
glycine in PBS at room temperature. Cells were incubated sequentially for 1 h each with 
primary and secondary antibodies (where applicable) in PBS containing 0.1% Triton X-100 
(or without Triton X-100, for non-permeabilized cells) supplemented with 3% BSA. Images 
were acquired with an LSM510 confocal microscope with a 63x, 1.4 NA oil-immersion lens 
(Zeiss). 
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Quantitative RT-PCR 
Total RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen). We subjected 
~1 μg of RNA to DNase I (amplification grade, Invitrogen) digestion and subsequently 
transcribed it into cDNA using random primers and Superscript II reverse transcriptase 
(Invitrogen). A 20-μl qRT-PCR reaction was set up using the Power SYBR Green PCR 
Master Mix (Applied Biosystems) and 0.5 µM of specific primers. Reactions were run in 
triplicates with a 60-s elongation time at 60°C. Amplification and melting curves were 
monitored using a StepOnePlus Real-Time PCR System and StepOne Software (Applied 
Biosystems). GAPDH was used as internal control and for ΔΔCt calculations. Primers were 
designed using the QuantPrime selection tool (37) to preferentially span exon-exon 
boundaries and to give products of 60–150 bp. The following primer pairs were used (5’-3’):  
GAPDH: ACAGTCAGCCGCATCTTCTT  and  GTTAAAAGCAGCCCTGGTGA 
LRRC8A: GGGTTGAACCATGATTCCGGTGAC  and  GAAGACGGCAATCATCAGCATGAC 
LRRC8B: ACCTGGATGGCCCACAGGTAATAG  and  ATGCTGGTCAACTGGAACCTCTGC 
LRRC8C: ACAAGCCATGAGCAGCGAC  and  GGAATCATGTTTCTCCGGGC 
LRRC8D: ATGGAGGAGTGAAGTCTCCTGTCG  and  CTTCCGCAAGGGTAAACATTCCTG 
LRRC8E: ACCGTGGCCATGCTCATGATTG  and  ATCTTGTCCTGTGTCACCTGGAG 
Electrophysiology 
HEK or HCT cells were plated onto gelatine-coated coverslips and transfected using Fugene 
HD (Promega) or Lipofectamine 2000 (Life Technologies) transfection reagents, respectively. 
One of the transfected LRRC8 isoforms was fused C-terminally to GFP. When LRRC8A was 
co-transfected with other LRRC8 isoforms only the latter carried GFP because plasma 
membrane fluorescence indicated co-expression with LRRC8A. 
Whole-cell voltage-clamp experiments were performed in isotonic extracellular solution 
containing (in mM) 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, and 10 HEPES, pH 7.4 
with NaOH (320 mOsm). ICl(swell) was elicited by perfusing the cells with hypotonic solution 
containing (in mM) 105 NaCl, 6 CsCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, 10 HEPES, pH 7.4 
with NaOH (240 mOsm). For anion selectivity experiments, NaCl was replaced in this 
solution by an equimolar amount of NaI, NaNO3, or Na-D-gluconate. The pipette solution 
contained (in mM) 40 CsCl, 100 Cs-methanesulfonate, 1 MgCl2, 1.9 CaCl2, 5 EGTA, 4 
Na2ATP, and 10 HEPES, pH 7.2 with CsOH (290 mOsm). Osmolarities of all solutions were 
assessed with an Osmomat 030 freezing point osmometer (Gonotec). All experiments were 
performed at constant temperature of 20–22°C. Currents were recorded with an EPC-10 
USB patch-clamp amplifier and PatchMaster software (HEKA Elektronik) or a MultiClamp 
700B patch-clamp amplifier/Digidata 1440A digitizer and pClamp 10 software (Molecular 
Devices). Patch pipettes had a resistance of 1–3 MΩ. Series resistance was compensated by 
80–90% to minimize voltage errors. Currents were sampled at 5 kHz and low-pass filtered at 
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10 kHz. The holding potential was -30 mV. Cells with a membrane resistance below 800 MΩ 
or series resistance above 10 MΩ were discarded. The standard protocol for measuring the 
time course of ICl(swell) activation, applied every 15 s after membrane rupture,  consisted of a 
0.6-s step to -80 mV followed by a 2.6-s ramp from -100 to 100 mV. The read-out for ICl(swell) 
was the steady-state whole-cell current at -80 mV normalized to the cell capacitance (current 
density) subtracted by the baseline current density at -80 mV before perfusion with hypotonic 
solution. The voltage protocol, applied after complete activation of ICl(swell), consisted of 1-s or 
2-s steps starting from -120 mV to 120 mV in 20-mV intervals preceded and followed by a 
0.5-s step to -80 mV every 5 s.  
Relative anion permeabilities (PX/PCl) were calculated from the shifts in reversal potential 
induced by perfusion with the anion substituted hypotonic salines using a modified Goldman-
Hodgkin-Katz equation:  
hypo subst
X Cl
subst
[Cl] exp [Cl]
/
[X]
revE F
RT
P P
 
  
   
 
where ΔErev is the shift in reversal potential, [Cl]hypo and [Cl]subst are the extracellular chloride 
concentrations in the normal and anion substituted hypotonic saline, and [X]subst is the 
concentration of the substituting anion. R is the gas constant, T is the absolute temperature, 
and F is the Faraday constant. Reversal potentials were determined by measuring 3 to 6 
cells for each cell line or transfection. Liquid junction potentials were measured for all 
solutions and corrected for in ion selectivity experiments. 
The inactivation kinetics of ICl(swell) could not be fitted appropriately by a single-exponential 
function. We therefore calculated the fraction of remaining current by dividing the current 
amplitude at the end of the 2-s voltage step by the current amplitude 1.5 ms after the 
beginning of the voltage step (avoiding contamination by capacitive transients). The half 
inactivation time t1/2 was determined by the time point where the inactivation reached half of 
the total inactivation after 2 s. Calculation of current densities and inactivation characteristics 
was carried out with an automatic script written in MATLAB R2011a (MathWorks) and plotted 
with GraphPad Prism 5 (GraphPad Software). Boltzmann curve-fitting and calculation of V1/2 
was done with GraphPad Prism with the following fitting constraints: bottom value less than 
0.2, top value greater than 0.9. Example current traces were lowpass-filtered at 2 kHz and 
reduced to a sampling rate of 1 kHz for clarity. Averaged data is presented as mean ± SEM. 
Significance was calculated by one-way ANOVA and Tukey’s post-hoc test, where 
applicable. At least 4 cells per condition were measured on at least two different days; exact 
n-values are given in the figures. Where possible, measurements were done blinded. 
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Deglycosylation, Co-immunoprecipitation and Western Blot 
To assess glycosylation of LRRC8A, HEK cells were transfected on 10-cm dishes using 17 µl 
of polyethylenimine (PEI) and 6 µg of plasmid encoding myc-tagged LRRC8A (wild-type or 
mutant). Cells were lysed in Ripa lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 4 mM Pefabloc (Roth), complete proteinase 
inhibitor cocktail (Roche)). After 10 min centrifugation at 14.000 rpm at 4°C, protein 
concentrations of cell lysates were determined by BCA assay. 60 µg of total protein were 
mixed with 2 µl of denaturing buffer (NEB) and 2 µl of 0.1 M Tris/HCl pH 7.4 in a reaction 
volume of 20 µl and denatured at 75°C for 10 min. Then 4 µl of 10xG7 Buffer (NEB), 4 µl of 
10% NP-40 (NEB) and 4 µl of PNGase F (Roche) were added in a total volume of 40 µl. After 
2 h incubation at 37°C, the reaction was terminated by adding 10 µl 5xLämmli sample buffer. 
Samples were separated by SDS-PAGE and analyzed by Western blot using the LRRC8A 
antibody. The experiment was repeated 3 times. 
For co-immunoprecipitation, HEK cells were co-transfected with plasmids (6 µg total) 
encoding myc-tagged or untagged LRRC8A and N-terminal fusion constructs of LRRC8A-E 
or ClC-1 (or soluble GFP) on 10-cm dishes using PEI as described above. 48 h post-
transfection cells were lysed in 300 µl lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 50 mM Tris-HCl pH 7.5, 4 mM Pefabloc (Roth), complete proteinase inhibitor 
cocktail (Roche)) for 10 min on ice. The lysate was pre-cleared by centrifugation at 
14.000 rpm for 10 min at 4°C and subsequently spun at 30.000 g for 30 min at 4°C. 150 µl of 
the supernatant were mixed with 10 µg of the respective antibody and IP buffer (150 mM 
NaCl, 0.1% NP-40; 0.05% sodium deoxycholate, 50 mM Tris-HCl, pH 7.5, complete 
proteinase inhibitor cocktail (Roche)) was added to final volume of 800 µl. The sample was 
rotated for 1-2 h at 4°C before 10 µl of Protein A Dynabeads® (Life Technologies) were 
added and rotation continued overnight at 4°C. After four washes with 500 µl IP buffer, 
precipitates were eluted in 40 µl Lämmli sample buffer, separated by SDS-PAGE and 
analyzed by Western blot as indicated. Lysate equivalent to 20% of input was loaded as 
reference. Experiments were repeated 3 times. 
For the immunoprecipitation from native cells, lysates from two confluent 15-cm plates per 
cell-line (wild-type and LRRC8A–/–) were prepared as described above. 1.9 ml lysate were 
mixed with equal volumes of IP buffer and 30 µl of Protein A Dynabeads® (Life Technologies) 
previously coupled to 15 µg of the LRRC8A antibody using dimethyl pimelimidate. After 
incubation and washing as described above, precipitates were eluted from the beads in 50 µl 
of 0.2 M glycine (pH 2.5), mixed with Lämmli sample buffer, separated by SDS-PAGE and 
analyzed by Western blot as indicated. 
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To assess protein expression, cells were lysed as described above. Protein concentrations 
were determined by BCA and equal amounts were separated by SDS-PAGE and analyzed 
by Western blot as indicated. 
Taurine Efflux Experiments 
HEK or HCT116 cells were grown to ~80% confluency (48-72 h after plating) in 35-mm 
diameter plates coated with poly-L-lysine. For rescue experiments, cells were transfected 
one day before flux measurements with LRRC8A and LRRC8C-GFP expression plasmids 
using Fugene HD. For these experiments, WT cells were mock transfected with a GFP 
expression vector. Cells were loaded with 3[H]-taurine (2 µCi/ml; Perkin-Elmer) for 2 to 2.5 h 
in culture medium (without FCS) at 37°C. They were then washed 7 times at room 
temperature with isotonic solution (in mM: 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, 
10 HEPES pH 7.4, 320 mOsm). After washing, external media were removed in 5-min 
intervals and replaced with fresh isotonic or hypotonic solution (in mM: 105 NaCl, 6 KCl, 1 
MgCl2, 1.5 CaCl2, 10 glucose, 10 HEPES pH 7.4, 240 mOsm) and saved for counting. At the 
end of the experiment, cells were lysed with 0.75 ml of 0.1 M NaOH. The radioactivity of cell 
supernatants and of the final cell lysate was determined in a liquid scintillation counter. 
Values presented were normalized to the total cellular radioactivity at that time point which 
was determined by adding the counts from the cell lysate and those of the supernatants 
collected at the corresponding and following time points. In each flux experiment, each data 
point represents the mean of 6 wells. 
RVD Measurements 
Cell volume was measured semiquantitatively using the calcein fluorescence method (38). 
HEK cells were plated 2 days before measurements at a density of 6,000 cells per well in a 
384-well plate. For the RVD assay, 10 µM calcein-AM (Affymetrix eBioscience) in DMEM 
were loaded for 1 h at 37°C and then washed 3 times with 80 µl isotonic solution (in mM: 145 
NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, 10 HEPES pH 7.4, 329 mOsm) using a Tecan 
Freedom EVO 200 workstation. Finally 10 µl of the isotonic solution were added to each well. 
After a 5-min incubation period the plate was transferred into the FLIPRTM (Molecular 
Devices) and fluorescence measurements at λ= 515-575 nm were initiated using the FLIPR 
Fluo4 LED/filter set. After baseline recording for 25 s, 25 µl aqua dest. were added to the 
wells resulting in a final osmolarity of 94 mOsm. Calcein fluorescence was monitored for ~65 
min. Wells containing cells of the respective cell-line not loaded with calcein-AM (but 
otherwise treated equally) were used for background subtraction, and fluorescence values 
were normalized to t= 30 s (after the pipetting procedure). Less pronounced swelling and 
RVD of WT HEK cells was observed under the conditions of our primary screen (exposure to 
189 mOsm) and RVD was likewise abolished in LRRC8A–/– cells (not shown). 
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Supplementary Figures 
 
 
Fig. S1. Effect of carbenoxolone on hypotonicity-induced YFP quenching by iodide. 
Fluorescence trace from a FLIPRTM experiment similar to those in Fig. 1C in which the effect 
of carbenoxolone (CBX), an inhibitor of VRAC and gap junctions (18), was investigated. 
Carbenoxolone was included in the I--containing solution and added at the time point 
indicated by arrow. 
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Fig. S2. Genome-wide RNA interference screen for VRAC. (A) Plate lay-out. Cells in wells 
of rows 1-22 were transfected with individual siRNAs of the Ambion Silencer® Human 
Genome siRNA Library V3 and tested for hypotonicity-induced YFP-quenching (experimental 
wells). Rows 23 and 24 contained control wells that were treated as indicated. (B) 
Photograph (inverted) of YFP fluorescence of an entire plate before the pipetting step (top) 
and at the end of the experiment (below). Note that fluorescence of cells treated with siRNA 
against YFP and cell-death inducing siRNA is strongly reduced at the beginning of the 
experiment (top) (transfection control). At the end of the experiment (bottom), fluorescence 
has remained strong in wells remaining in isotonic solution throughout. Arrows indicate well 
H11 containing cells transfected with the most efficient siRNA against LRRC8A. (C) Heat 
map of the same plate. Z-scores for Smax (maximal slope of quenching) are displayed using 
the color scale shown at right.   
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Fig. S3. Analysis of the primary, genome-wide siRNA screen for VRAC. (A and B) 
Parameters derived from the primary siRNA screen for VRAC. (A) Example of original data 
obtained from the FLIPRTM primary genome-wide screen, showing the absolute, non-
corrected values of fluorescence (Fabs) measured at λ = 526-585 nm as a function of time. 
The green curve shows a representative trace from an experimental well with YFP-
expressing HEK cells that have been treated with siRNA and were exposed to hypotonic, 
iodide-containing solution at the time indicated by the arrow. The brown curve shows a 
control well from the same plate to which hypotonic, iodide-containing solution containing 1% 
Triton X100. (B) Background-subtracted and normalized fluorescence F*. After subtracting 
the background determined in control wells treated with Triton X100, the fluorescence of 
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every experimental well was normalized to its individual Fabsstart value. The maximal slope of 
fluorescence decrease Smax was determined by linear regression to the curve between 35 
and 300 seconds and was used as main parameter to identify hits. tonset was defined as 
indicated and can be used as measure of the speed of signal transduction between volume 
increase and VRAC opening. (C and D) Fidelity of replicate screens. Correlation of Z-scores 
of maximal slope Smax between the original and the replicate screen observed with all 65,061 
siRNAs (C) and after filtering out those measurements that were flagged for low cell number 
or did not reach near-steady-state fluorescence by the end of the measurement (D). Z-scores 
from screen 1 and screen 2 are plotted on the x- and y-axis, respectively. The Pearson 
correlation coefficient (r=0.62 and r=0.65, respectively) indicates positive correlation between 
replicate screens. The regression line from simple linear regression is shown as a dashed 
red line. The elimination of outliers demonstrated the usefulness of these warning flags. (E) 
Histogram of Z-scores for maximal slope (Smax) from the genome-wide siRNA screen. 
Measurements which were flagged for low cell number or did not reach steady state 
fluorescence by the end of measurement were filtered out, resulting in values for 50,258 
siRNAs. The averaged Z-scores from screen 1 and screen 2 are plotted. Arrows indicate the 
Z-scores of three individual siRNAs against LRRC8A (0.125, 0.809 and 2.217).  
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Fig. S4. Subcellular localization of LRRC8 proteins. (A) Plasma membrane localization of 
LRRC8A-GFP transfected into HeLa cells detected by GFP labeling. (B) Truncated LRRC8A 
fused at R719 to GFP failed to reach the plasma membrane. This truncation mimics the 
effect of a chromosomal translocation at the LRRC8A that was found in a patient with 
agammaglobulinemia (21). (C-E) Intracellular localization of LRRC8B, D and E when 
transfected alone (for LRRC8C, see Fig 1I). (F-H) LRRC8B, D and E reach the plasma 
membrane when co-transfected with LRRC8A (for LRRC8C, see Fig 1J). Insets, 
magnification of boxed areas showing exclusively GFP fluorescence. Scale bar, 10 μm for all 
panels. 
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Fig. S5. Absence of ICl(swell) in independent LRRC8A
-/- cell lines. (A) Example ICl(swell) traces 
(as in Fig. 1E, but 2-s pulses) of WT and mutant HEK cells (clone 3E7). When transfected 
into HEK LRRC8A-/- cells, LRRC8A rescues ICl(swell). (B) Amplitudes of maximally activated 
ICl(swell) (at -80 mV) of WT HEK, WT HCT116 and different LRRC8A
-/- cell lines, rescued by 
transfection of LRRC8A-GFP cDNA. Note that the amplitude of ICl(swell) current was not fully 
rescued in HEK cells by LRRC8-GFP transfection, an observation that fits to the suppression 
of ICl(swell) from native HEK cells by LRRC8A transfection (Fig. 1F). Mean currents ± SEM, 
number of measurements is indicated. **, p<0.01 and ***, p<0.001 compared to WT HEK or 
WT HCT116, respectively. For description of different cell lines see table S4.  
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Fig. S6. Characterization of ICl(swell) in HCT116 cells. (A) Relative anion permeabilities 
(PX/PCl) as determined from shifts in reversal potential of ICl(swell) upon anion substitution in 
WT, LRRC8 knock-out HCT116 cell lines, and (B) LRRC8-/- cells transfected with the 
combinations indicated. Mean ± SEM, number of cells ≥ 4. (C) Example current-voltage 
relationships obtained at the time of maximal current activation of endogenous and 
reconstituted ICl(swell) with normal and anion substituted hypotonic extracellular solutions. The 
reversal potential is shifted to slightly more negative voltages when extracellular Cl- is 
replaced by I- and NO3
- and to drastically more positive voltages upon replacement by D-
gluconate. (D-E) Voltage-dependent ICl(swell) inactivation assessed by time needed to 
inactivate to 50% of the difference between currents at end / beginning of pulse (I2sec/Imax). In 
panel E, constructs were transfected into the quintuple KO HCT116 cell line (LRRC8-/-). 
Numbers in brackets indicate the number of cells measured. 
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Fig S7. Relative LRRC8 mRNA expression. LRRC8A – E mRNA expression in HEK, 
HCT116, and HL-60 cells determined by quantitative RT-PCR. Values were normalized to 
the respective value of HEK cells. Values represent the means from 4 experiments. Error 
bars indicate SEM. 
 
 
 
 
 
Fig. S8. Heteromerization of endogenous LRRC8 proteins. LRRC8A co-precipitated 
LRRC8E (for which a suitable antibody was available) in immunoprecipitation with an 
LRRC8A antibody from wild-type (WT) HEK cell lysate, but not from the LRRC8A-/- knockout 
(KO, clone 3E7).The plasma membrane ion transporter KCC1 (negative control) did not co-
precipitate with LRRC8A. Lysate equivalent to 25% of input was loaded as reference (input).  
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Fig. S9. LRRC8A is crucial for swelling-induced 3[H]-taurine efflux in HEK cells.  
(A) One set of wild-type (WT) HEK cells were in isotonic solution throughout, whereas 
another set of WT or LRRC8A-/- HEK cells were exposed to hypotonic solution starting at t=0 
(arrow). Bars represent means of 6 measurements of taurine efflux between the indicated 
time points. Error bars indicate SEM. (B) Taurine efflux measurement as in (A), but the 
LRRC8A-/- HEK cells had been co-transfected with LRRC8A and LRRC8C-GFP. This co-
transfection partially restores the taurine flux capability of LRRC8A-/- HEK cells. Co-
transfection was necessary as overexpression of LRRC8A alone leads to a suppression of 
ICl(swell). Only partial rescue of fluxes with transfected cells agrees with the transfection 
efficiency of roughly 50%.  
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Fig. S10. Characterization of LRRC8A and LRRC8E antibodies. (A) Western blots of 
lysates from wild-type (WT) and LRRC8A-/- (clone 3F8) HCT116 cells, and from HeLa cells 
that were not transfected (n.t.), or transfected with LRRC8A or with LRRC8A and LRRC8C 
GFP fusion proteins were probed with the LRRC8A antibody, or antibodies against GFP and 
α-tubulin (loading control) as indicated. The LRRC8A antibody recognizes native and 
overexpressed LRRC8A specifically. (B) Western blots of lysates from WT, LRRC8A-/- (clone 
4B9) and LRRC8E-/- (clones BCDE(WT)-F5 and CE(WT)-B6) HCT116 cells, and from HeLa 
cells that were not transfected (n.t.) or transfected with LRRC8A or LRRC8E GFP fusion 
proteins were probed with antibodies against LRRC8A, LRRC8E and α-tubulin. The LRRC8E 
antibody recognizes specifically native and overexpressed LRRC8E, whereas LRRC8E is not 
recognized by the LRRC8A antibody. (C) HeLa cells methanol-fixed and immunostained with 
the LRRC8A antibody (red in overlay) 24 h after transfection with LRRC8A (upper panel) and 
LRRC8C (bottom panel) GFP fusion proteins (GFP signal, green in overlay), nuclei in blue. 
The LRRC8A antibody recognizes specifically overexpressed LRRC8A. Scale bars, 20 µm. 
(D) Higher exposure of non-transfected HeLa cells reveals plasma membrane staining with 
the LRRC8A antibody (red; nuclei in blue). Scale bar, 20 µm.    
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Supplementary Tables 
 
Table S1. List of anion transporters tested by siRNA interference in HEK cells in a 
FLIPRTM prescreen. 
 
Gene name Alternative name(s) Proposed function 
ANO1 Anoctamin1, TMEM16A Ca
2+
-activated Cl
-
 channel 
ANO3 Anoctamin3, TMEM16C Ca
2+
-activated Cl
-
 channel (?) 
ANO4 Anoctamin4, TMEM16D Ca
2+
-activated Cl
-
 channel (?) 
ANO5 Anoctamin5, TMEM16E Ca
2+
-activated Cl
-
 channel (?) 
ANO6 Anoctamin6, TMEM16F Ca
2+
-activated Cl
-
 or cation channel, scramblase 
ANO7 Anoctamin7, TMEM16G Ca
2+
-activated Cl
-
 channel (?) 
ANO8 Anoctamin8, TMEM16H Ca
2+
-activated Cl
-
 channel (?) 
ANO9 Anoctamin9, TMEM16J Ca
2+
-activated Cl
-
 channel (?) 
ANO10 Anoctamin10, TMEM16K Ca
2+
-activated Cl
-
 channel (?) 
CLCN3 ClC-3 Cl
-
/H
+
-exchanger, wrongly claimed to be VRAC 
BEST1 Bestrophin 1 Ca
2+
-activated Cl
-
 channel 
BEST2 Bestrophin 2 Ca
2+
-activated Cl
-
 channel 
SLC4A2 AE2, anion exchanger 2 Cl
-
/HCO3
-
 exchanger 
SLC4A3 AE3, anion exchanger 3 Cl
-
/HCO3
-
 exchanger 
SLC12A2 NKCC1 NaK2Cl cotransporter 
SLC12A4 KCC1 KCl cotransporter 
SLC12A6 KCC3 KCl cotransporter 
SLC12A7 KCC4 KCl cotransporter 
SLC26A1 SAT1 anion exchanger, sulfate transporter 
SLC26A9  anion transporter  
SLC26A11 KBAT Na
+
-dependent sulfate transporter, Cl
-
 channel (?) 
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Table S2. List of candidate genes from genome-wide siRNA screen that were taken 
into a secondary FLIPRTM RNA interference screen using SMARTpools of independent 
siRNAs.  
 
 
Gene ID Gene symbol TMDs* Z-score
†
  Gene ID Gene symbol TMDs* Z-score
†
 
1 3371 TNC 1 2.6931 45 51338 MS4A4A 4 1.3255 
2 79652 TMEM204 4 2.3119 46 92255 DKFZp434H2226 9 1.3153 
3 253558 ALCAT1 3 2.1069 47 79762 FLJ14146 1 1.3139 
4 54879 ST7L 2 1.9163 48 159371 TMEM20 10 1.3091 
5 5793 PTPRG 1 1.8685 49 79683 ZDHHC14 4 1.3016 
6 28959 LR8 / TMEM176B 4 1.8351 50 65062 ALS2CR4 4 1.2954 
7 51234 EMC4 2 1.7410 51 79844 ZDHHC11 5 1.2780 
8 10098 TM4SF9/TSPAN5 4 1.7358 52 10100 TSPAN-2 4 1.2743 
9 125111 GJC1/GJD3 4 1.7326 53 123606 NIPA1 8 1.2581 
10 29940 SART2 3 1.6643 54 55362 TMEM63B 11 1.2448 
11 284723 SLC25A34 2 1.6399 55 124491 TMEM170A 3 1.2369 
12 130814 PQLC3 4 1.6306 56 56674 TMEM9B 2 1.2335 
13 23505 RW1/TMEM131 2 1.6096 57 94015 TTYH2 6 1.2300 
14 199953 TMEM201 6 1.5948 58 203562 TMEM31 2 1.2116 
15 80759 KHDC1 2 1.5846 59 27069 GHITM 6 1.2099 
16 9415 FADS2 4 1.5817 60 26526 TM4-B 3 1.1928 
17 57484 RNF150 2 1.5569 61 81671 VMP1 6 1.1703 
18 54741 OBRGRP 4 1.5488 62 374882 TMEM205 4 1.1329 
19 5348 FXYD1 1 1.5477 63 10712 Fam189B 4 1.1222 
20 56172 ANKH 8 1.5316 64 85414 Prostein/SLC45A3 11 1.1208 
21 4034 LRCH4 1 1.5303 65 91147 TMEM67 4 1.1122 
22 57198 ATP8B2 9 1.5268 66 57348 TTYH1 5 1.0725 
23 53346 TM6SF1 9 1.5216 67 128506 OCSTAMP 6 1.0707 
24 120224 TMEM45B 5 1.5205 68 55852 TEX2 2 1.0702 
25 56262 LRRC8A 4 1.5129 69 93109 TMEM44 4 1.0630 
26 10959 RNP24 2 1.4911 70 11161 C14orf1 4 1.0598 
27 79022 TMEM106C 2 1.4885 71 64137 ABCG4 7 1.0392 
28 349149 GJE1/GJC3 3 1.4769 72 29097 HSPC163 3 1.0315 
29 746 TMEM258 2 1.4751 73 55625 ZDHHC7 4 1.0268 
30 53827 FXYD5 1 1.4684 74 64429 ZDHHC6 4 1.0165 
31 55009 C19orf24 2 1.4654 75 54860 MS4A12 4 1.0130 
32 29058 C20orf30 2 1.4566 76 162427 FAM134C 3 1.0120 
33 10099 TM4SF8/ TSPAN3 4 1.4361 77 23460 ABCA6 13 1.0099 
34 54929 TMEM161A 8 1.4268 78 9906 SLC35E2 3 0.9891 
35 84561 SLC12A8 10 1.4140 79 64645 HIAT1 12 0.9848 
36 113829 SLC35A4 9 1.4016 80 345274 SOAT/SLC10A6 8 0.9758 
37 29956 LASS2 5 1.3728 81 347735 TDE2L/SERINC2 11 0.9695 
38 145407 C14orf37 2 1.3710 82 55002 TMCO3 10 0.9674 
39 51522 TMEM14C 4 1.3670 83 202915 TMEM184A 7 0.9488 
40 55739 FLJ10769 1 1.3656 84 8082 SSPN 4 0.9236 
41 284099 C17orf78 1 1.3551 85 84548 FAM11A/TMEM185A 8 0.9025 
42 81555 SMAP-5 4 1.3487 86 135656 DPCR1 2 0.8911 
43 57181 SLC39A10 7 1.3480 87 85013 TMEM128 4 0.7763 
44 7355 SLC35A2 8 1.3401      
 
*predicted number of transmembrane domains 
†
mean Z-score for Smax of  the two ‘best’ siRNAs from 2 replicate primary screens 
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Table S3. Clonal cell lines with disrupted LRRC8 genes. 
 
Cell line Clone name Construct used* Genetic modification Protein modification  Used for figure 
LRRC8A
-/-
 
(HEK) 
3E7 
 
 
3A 
 
 
a1: Δ21nt (t110-a130) 
 
a2: insertion of 1 nt  
(t after c123) 
A1: ΔM37-G43 in TMD1 
(non- functional) 
A2: G42W-fs in TMD1  
Fig.1H; Fig. 2A;  
Fig. 4B; fig. S5;  
fig. S8; fig. S9 
1F7 1A a1: Δ9nt (a958-g966) 
 
a2: Δ2nt (c965-g966) 
a3: Δ23nt (a958-g980) 
A1: ΔI320-A322 at start of TMD4(non- 
functional) 
A2: A322V-fs at start of TMD4 
A3: I320P-fs at start of TMD4 
Fig. 2A; fig. S5B 
LRRC8A
-/- 
(HCT116) 
3F8 3A Δ2g out of 6g (g124-g129) G43D-fs in TMD1 Fig. 2A, 2B, 2C;  
fig. S5B; fig. S6A;  
fig. S10A 
4B9 4A a1: Δ32nt (c195-g226) 
a2: duplication of t206 
A1: C65W-fs between TMD1 and TMD2 
A2: R70P-fs between TMD1 and TMD2 
Fig. 2A; Fig. 4A;  
fig. S5B; fig. S10B 
ZF9 ZFN a1: Δ2nt (a508-c509) 
a2: insertion of 5nt (cacga after 
a511) 
A1: T170E-fs between TMD2 and TMD3 
A2: R171T-fs between TMD2 and TMD3 
Fig. 2A; fig. S5B 
LRRC8B
-/-  
(HCT116) 
n2B-D3 2B duplication of t446 E150R-fs after TMD2 Fig. 2B, 2C, 2D; 
fig. S6A, S6D 
LRRC8C
-/-  
(HCT116) 
n1C-C2 1C duplication of t119 F41V-fs in TMD1 Fig. 2B, 2C, 2D;  
fig. S6A, S6D 
LRRC8D
-/-  
(HCT116) 
n1D-F11 1D a1: Δ19nt (a325-t343) 
a2: duplication of a325 
D1: P110L-fs between TMD1 and TMD2 
D2: I109N-fs between TMD1 and TMD2 
Fig. 2B, 2D; fig. S6D 
data from both clones 
pooled for: Fig. 2C 
fig. S6A 
n1D-B2 1D duplication of a325 I109N-fs between TMD1 and TMD2 
LRRC8E
-/- 
(HCT116) 
BCDE(WT)-F5 1E duplication of a94 T32N-fs in TMD1 Fig. 2B; fig. S6A 
both clones: fig. S10B 
data from both clones 
pooled for: 
Fig. 2C, 2D; fig. S6D 
CE(WT)-B6 1E duplication of a94 T32N-fs in TMD1 
LRRC8(D/E)
-/- 
(HCT116) 
nBCDE 
(WT)-G9 
1D, 1E 
 
D: duplication of a325 D: I109N-fs between TMD1 and TMD2 Fig. 2B; fig. S6A 
 
data from both clones 
pooled for: 
Fig. 2C, 2D; fig. S6D 
E: duplication of a94 E: T32N-fs in TMD1 
nBCDE 
(WT)-B3 
1D, 1E D: duplication of a325 D: I109N-fs between TMD1 and TMD2 
E: duplication of a94 E: T32N-fs in TMD1 
LRRC8(C/E)
-/- 
(HCT116) 
BCDE(WT)-
F5+1C-D5 
 
1C, 1E C:  a1: duplication of t119 
 a2: Δ5nt (c114-g118) and 
 duplication of t119 
C1: F41V-fs in TMD1 
C2: G39C-fs in TMD1 
Fig. 2B, 2C, 2D;  
fig. S6A, S6D 
E: duplication of a94 E: T32N-fs in TMD1 
LRRC8(C/D/E)
-/- 
(HCT116)
 
nBCDE(WT)-H8 1C, 1D, 1E C: 78nt (from a66 onwards) incl. 
splice acceptor site replaced by 
13 nt (net Δ65nt) 
C: W23R-fs at start of TMD1, before 
missing splice site 
Fig. 2B, 2C 
D:  a1: duplication of a325 
    
 a2: Δ11nt (g322-t332) 
D1: I109N-fs between TMD1 and TMD2 
D2: D108Q-fs between TMD1 and TMD2  
E:  a1: duplication of a94 
 a2: Δ10nt (g87-c96) 
E1: T32N-fs in TMD1 
E2: Y30W-fs in TMD1 
LRRC8(B/C/D/E)
-/- 
(HCT116) 
BCDE 
(WT2)-D2+2B-E8 
2B,1C, 1D, 1E B:  a1: duplication of t446 
 a2: Δ2nt (c447-g448) 
B1: E150R-fs after TMD2 
B2: E150A-fs after TMD2 
Fig. 2B, 2C; Fig. 4A 
C: duplication of t119 C: F41V-fs in TMD1 
D: duplication of a325 D: I109N-fs between TMD1 and TMD2 
E: Δ2nt (t92-c93) E: L31H-fs in TMD1 
LRRC8
-/- 
(HCT116) 
BC+DE 
(KO)D5+ 
2B-G4 
3A, 2B, 1B
§
, 1C, 
1D, 1E 
A: Δ2g out of 6g (g124-g129)  A: G43D-fs in TMD1 Fig. 2E, 2F, 2G;  
fig. S6B, S6C, S6E  
B:  a1: duplication of t446 
 a2: Δ4nt (c447-g450) 
B1: E150R-fs after TMD2 
B2: E150I-fs after TMD2 
C: duplication of t119 C: F41V-fs in TMD1 
D: duplication of a325 D: I109N-fs between TMD1 and TMD2 
E: duplication of a94 E: T32N-fs in TMD1 
 
a = allele (only given if alleles differed in modifications); fs = frameshift; nt = nucleotide; TMD = transmembrane domain; ZFN = zinc-finger nuclease; Δ = deletion 
Indicated nucleotide numbers give nucleotide position within the ORF. 
* For targeted guide sequences, see table S4. 
§
 Targeting with construct 1B in LRRC8
-/-
 cell line resulted in a duplication of a1043 which would lead to A349G-fs after TMD4. However, the mutations by the 2B 
 targeting (given in table) truncate LRRC8B already after TMD2. 
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Table S4. Guide sequences used for the generation of knock-out cell lines with the 
CRISPR/Cas system. 
 
Target gene Construct Guide sequence (5’3’)  Targeting strand Target location in protein 
LRRC8A 
 
 
1A 
3A 
4A 
ggctgatgtagaaggacgccagg 
tgatgattgccgtcttcgggggg 
tcctgcaatgattcgttccgggg 
- 
+ 
+ 
aa 320-328 (beginning of TMD4) 
aa 36-43 (in TMD2) 
aa 64-71 (between TMD1 and TMD2) 
LRRC8B 1B 
2B 
tttttctcttaacgcctcaaagg 
ggccacaaaatgctcgagcctgg 
- 
- 
aa 346-353 (after TMD4) 
aa 147-354 (between TMD2 and TMD3) 
LRRC8C 1C atgctcatgatcggcgtgtttgg + aa 35-42 (in TMD1) 
LRRC8D 1D gtggctctgagaggtatgtcagg - aa 107-114 (between TMD1 and TMD2) 
LRRC8E 1E gctggccgagtacctcaccgtgg + aa 27-34 (inTMD1) 
 
aa= amino acid; TMD = transmembrane domain; PAM sequences are underlined 
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